Company: INTS
Filing Date: 2025-04-22
Form Type: S-1
Source: 0001628280-25-018892
Chunk: 37

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-04-22
Form: S-1
Chunk 37
---
 system. Without an active trading market, the liquidity of the Common Warrants will be limited.

#### Rights as a Shareholder.
Except as otherwise provided in the Series B-1 Common Warrants or by virtue of the holders’ ownership of shares of our Common Stock, the holders of Series B-1 Common Warrants do not have the rights or privileges of the holders of our Common Stock, including any voting rights, until such Series B-1 Common Warrant holders exercise their warrants.

#### Fundamental Transaction.
If a fundamental transaction occurs, then the successor entity will succeed to, and be substituted for us, and may exercise every right and power that we may exercise and will assume all of our obligations under the Series B-1 Common Warrants with the same effect as if such successor entity had been named in the Series B-1 Common Warrant itself. If holders of our common shares are given a choice as to the securities, cash or property to be received in a fundamental transaction, then the holder shall be given the same choice as to the consideration it receives upon any exercise of the Series B-1 Common Warrant following such fundamental transaction. Additionally, as more fully described in the form of warrant, in the event of certain fundamental transactions, the holders of the Series B-1 Common Warrants will be entitled to receive consideration in an amount equal to the Black Scholes value of the Series B-1 Common Warrants on the date of consummation of the transaction.

Series B-2 Common Warrants to be Issued in this Offering

The following is a summary of the material terms and provisions of the Series B-2 Common Warrants that are being offered hereby. This summary is subject to and qualified in its entirety by the form of Series B-2 Common Warrant, which will be filed with the SEC as an exhibit to a Current Report on Form 8-K in connection with this offering and incorporated by reference into the registration statement of which this prospectus supplement and the accompanying prospectus form a part. Prospective investors should carefully review the terms and provisions of the form of warrant for a complete description of the terms and conditions of the warrants.

#### Duration and Exercise Price.
The Series B-2 Common Warrants offered hereby will have an exercise price of $1.88 per share (the assumed combined offering price per share of Common Stock and accompanying Common Warrants (the closing price of our Common Stock on Nasdaq on April 21, 2025)). The Series B-2 Common Warrants are exercisable beginning on